Amplia Therapeutics Limited Stock Probability of Future Pink Sheet Price Finishing Under 0.0006
| INNMF Stock | USD 0.06 0.01 14.49% |
Amplia |
Amplia Therapeutics Target Price Odds to finish below 0.0006
The tendency of Amplia Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 0.0006 or more in 90 days |
| 0.06 | 90 days | 0.0006 | near 1 |
Based on a normal probability distribution, the odds of Amplia Therapeutics to drop to $ 0.0006 or more in 90 days from now is near 1 (This Amplia Therapeutics Limited probability density function shows the probability of Amplia Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Amplia Therapeutics price to stay between $ 0.0006 and its current price of $0.059 at the end of the 90-day period is about 6.79 .
Assuming the 90 days horizon Amplia Therapeutics Limited has a beta of -0.53. This usually indicates as returns on the benchmark increase, returns on holding Amplia Therapeutics are expected to decrease at a much lower rate. During a bear market, however, Amplia Therapeutics Limited is likely to outperform the market. Additionally Amplia Therapeutics Limited has an alpha of 0.8588, implying that it can generate a 0.86 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Amplia Therapeutics Price Density |
| Price |
Predictive Modules for Amplia Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Amplia Therapeutics. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Amplia Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Amplia Therapeutics is not an exception. The market had few large corrections towards the Amplia Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Amplia Therapeutics Limited, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Amplia Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.86 | |
β | Beta against Dow Jones | -0.53 | |
σ | Overall volatility | 0.02 | |
Ir | Information ratio | 0.04 |
Amplia Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Amplia Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Amplia Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Amplia Therapeutics is way too risky over 90 days horizon | |
| Amplia Therapeutics has some characteristics of a very speculative penny stock | |
| Amplia Therapeutics appears to be risky and price may revert if volatility continues | |
| Amplia Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 2.99 M. Net Loss for the year was (3.64 M) with profit before overhead, payroll, taxes, and interest of 1.83 M. | |
| Amplia Therapeutics Limited has accumulated about 14.61 M in cash with (4.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 22.0% of the company shares are held by company insiders | |
| Latest headline from zacks.com: Forte Biosciences Upgraded to Buy What Does It Mean for the Stock |
Amplia Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Amplia Pink Sheet often depends not only on the future outlook of the current and potential Amplia Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Amplia Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 193.9 M |
Amplia Therapeutics Technical Analysis
Amplia Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Amplia Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Amplia Therapeutics Limited. In general, you should focus on analyzing Amplia Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Amplia Therapeutics Predictive Forecast Models
Amplia Therapeutics' time-series forecasting models is one of many Amplia Therapeutics' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Amplia Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Amplia Therapeutics
Checking the ongoing alerts about Amplia Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Amplia Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Amplia Therapeutics is way too risky over 90 days horizon | |
| Amplia Therapeutics has some characteristics of a very speculative penny stock | |
| Amplia Therapeutics appears to be risky and price may revert if volatility continues | |
| Amplia Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 2.99 M. Net Loss for the year was (3.64 M) with profit before overhead, payroll, taxes, and interest of 1.83 M. | |
| Amplia Therapeutics Limited has accumulated about 14.61 M in cash with (4.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 22.0% of the company shares are held by company insiders | |
| Latest headline from zacks.com: Forte Biosciences Upgraded to Buy What Does It Mean for the Stock |
Other Information on Investing in Amplia Pink Sheet
Amplia Therapeutics financial ratios help investors to determine whether Amplia Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amplia with respect to the benefits of owning Amplia Therapeutics security.